Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
2002
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Pancreatic cancer
2004 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Emerging evidence on the pathobiology of mucositis
2013
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
A Systematic Review of Quality of Life Associated with Standard Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer
2007
The treatment of advanced non-small cell lung cancer
2005
The evolution of cancer research and drug discovery at Lilly Research Laboratories
2005
Cancer drug resistance: an evolving paradigm
2013 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Introduction of Fluorine and Fluorine‐Containing Functional Groups
2013 Standout
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
2007
Molecular mechanisms of cisplatin resistance
2011 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
2000
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
2006 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Chemotherapy and the war on cancer
2005 Standout
Emerging evidence on the pathobiology of mucositis
2013
Cetuximab in advanced non-small cell lung cancer
2006
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
2005
Metastatic Colorectal Cancer
2007
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study
2007
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
2006
Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
2003
Role of gemcitabine in cancer therapy
2005
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial
2000
Natural compounds for cancer treatment and prevention
2009 Standout
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549
2004
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non–Small-Cell Lung Cancer
2000
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
2002
Disclosure of competing financial interests and role of sponsors in phase III cancer trials
2005
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Interstitial Lung Disease in Lung Cancer
2005
The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer
2006
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
Anemia of Chronic Disease
2005 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Industry sponsorship and research outcome
2012 Standout
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin
2001
Contribution of Organofluorine Compounds to Pharmaceuticals
2020 Standout
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial
2004
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
1999
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
2002
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer
2002
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
2002
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
The genus Scutellaria an ethnopharmacological and phytochemical review
2010 Standout
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
2002
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma
2002
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
2000
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
2002
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
2001
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Industry sponsorship and research outcome
2017 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of M. Lomas being referenced
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
2004
Gemcitabine/Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines: Results of a Phase II Trial
2003
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer
2008
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
1999